If Doctors Use Your Data To Develop Treatments, Do They Need To Tell You?
Ethicists, patients, doctors and courts are wrestling with that question as efforts grow to expand care through better data and technology. Also, Stat offers a guide to CRISPR, and Madrigal Pharmaceuticals says one of its drugs has shown progress treating fatty liver disease.
NPR:
When Scientists Develop Products From Personal Medical Data, Who Gets To Profit?
If you go to the hospital for medical treatment and scientists there decide to use your medical information to create a commercial product, are you owed anything as part of the bargain? That's one of the questions that is emerging as researchers and product developers eagerly delve into digital data such as CT scans and electronic medical records, making artificial-intelligence products that are helping doctors to manage information and even to help them diagnose disease. (Harris, 5/31)
Stat:
CRISPR Advances Are Coming Fast. Here’s Your Guide
It lists studies from research journals, company announcements, and preprints, chosen because they reported a key advance in either the genome-editing technology or the diseases that might be treated with it. It also links to the research papers, though not all are open access (sorry). We’re not including everything, but we hope CRISPR Trackr gives you a sense of how quickly things are moving. We’ll update it as needed. (Begley, 6/1)
Stat:
With Positive Data, Madrigal Joins Lucrative Race To Treat Fatty Liver Disease
Nine months of treatment with an experimental pill from Madrigal Pharmaceuticals resulted in the significant reversal of the fatty liver disease known as NASH, according to updated data from a placebo-controlled clinical trial released Thursday. A significantly greater number of patients taking the Madrigal drug also saw NASH liver symptoms resolve completely. There was a more modest reduction in the most troublesome tissue-scarring process known as fibrosis. The Madrigal drug is called MGL-3196. (Feuerstein, 5/31)
